Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PBRM1 | Q86U86 | 10/20 | 0.56 |
| ▸ | SMARCA2 | P51531 | 9/20 | 0.56 |
| ▸ | SMARCA4 | P51532 | 9/20 | 0.56 |
| ▸ | NR1I2 | O75469 | 4/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | SCN4A | P35499 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26683528 | 0.82 | PBRM1 (0.40) | PBRM1SMARCA2SMARCA4NR1I2BRD4 | |
| SCHEMBL27172047 | 0.75 | PBRM1 (0.41) | PBRM1SMARCA2SMARCA4NR1I2BRD4 | |
| SCHEMBL26888980 | 0.74 | SMARCA2 (0.57) | PBRM1SMARCA2SMARCA4NR1I2HTR7 | |
| SCHEMBL31570178 | 0.74 | SMARCA2 (0.57) | PBRM1SMARCA2SMARCA4NR1I2HTR7 | |
| SCHEMBL26685303 | 0.74 | SMARCA2 (0.57) | PBRM1SMARCA2SMARCA4NR1I2HTR7 | |
| SCHEMBL26683624 | 0.74 | PBRM1 (0.41) | PBRM1SMARCA2SMARCA4NR1I2BRD4 | |
| SCHEMBL26683281 | 0.73 | BPTF (0.44) | CYP1A2SCN4ASCN9AHTR2CHTR7 | |
| SCHEMBL26653859 | 0.72 | PBRM1 (0.55) | PBRM1SMARCA2SMARCA4NR1I2CYP1A2 | |
| SCHEMBL29936408 | 0.72 | PBRM1 (1.00) | PBRM1SMARCA2SMARCA4NR1I2BRD4 | |
| SCHEMBL18038799 | 0.72 | PBRM1 (1.00) | PBRM1SMARCA2SMARCA4NR1I2BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304596-A1 | PYRAZINE DERIVATIVES AND USES THEREOF | FOGHORN THERAPEUTICS INC (US) | 2025-10-02 | — | — | US | disclosed |
| EP-4522277-A1 | PYRAZINE DERIVATIVES AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| WO-2023220137-A1 | PYRAZINE DERIVATIVES AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023220137-A1 | PYRAZINE DERIVATIVES AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2023-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304596-A1 | PYRAZINE DERIVATIVES AND USES THEREOF | VHL, BRCA1, SF3B5 | PBRM1 9/4885SMARCA2 67/4885SMARCA4 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.